Capital.
Forecast.
Story.
What you allocate this year is the story your board reads next year.
This briefing tells you which capital-allocation decisions become 10x bets in pharma sales as AI compresses the cost stack. Read it before your peers send their version to the board.
The 10-page briefing. Worth 20 minutes.
One email. One PDF. Worth twenty minutes of your week.
We send it once. Work emails only.
Every commercial CFO at a European pharma affiliate has had the same Tuesday morning. Three things on the screen before 09:00. Uptake on your flagship launch is tracking four months behind plan against a 50M SEK peak annual revenue, and under the patent clock that gap is gross profit that does not come back. Your vendor CRM AI bundle landed in SG&A last quarter without a rep-force or medical-affairs re-plan. LoE on the brand that carries a third of your contribution margin hits in eighteen months, and only one in-licensing candidate is slotted into the bridge.
You have signed ten launch forecasts for this Regional. The pattern used to be simple. Size the rep force. Resource medical affairs. Fund market access. Close ex-factory clean. The job has not changed in fifty years. The bar has risen on every measure of doing it, simultaneously, and the equation that matters most is the one it has always been: time-to-peak under the patent clock.
The commercial-intelligence decision is not a CRM-licence request. It is the largest single capital-allocation decision you will make this portfolio.
This is the question your Regional VP is already asking. The briefing below is what you want in your hand before the next launch review.
Capital Allocation. Forecast Credibility. Value-Creation Narrative.
Three questions every commercial CFO is tracking. The first is the crux. The other two are how you earn the right to answer it.
How does the next €5-10M of envelope actually compound?
Rep-force sizing, medical-affairs depth, market-access resource, CRM AI licences, commercial-intelligence infrastructure, in-licensing candidate. Today's default: five requisitions from five function heads. The vendor sells licences straight into Commercial Ops. Capital-allocation authority slides away from the seat.
Why is uptake printing below plan, and what is the asset-level story?
Your Regional voted on a launch curve built before the last JCA cycle. Your print is tracking four months behind peak. Your Head of FP&A cannot walk the next Regional call through the asset-level story. The formulary signal sits with Market Access. The prescribing signal sits with Medical Affairs. The competitor-launch signal sits in Public Affairs.
What does this affiliate do that holds GP against the LoE cliff?
Your Regional VP wants the portfolio review. Your Global CFO wants the LoE-exposure note. Your compliance officer wants the AI-governance position. Three audiences, three documents, three teams, and the numbers underneath them do not match.
What you get when you download
An 11-page report for Commercial CFOs at European pharma affiliates. Designed to be read in one sitting before your next Regional review.
Your industry, your finance function, and why they are one problem
What is happening in European pharma commercialisation as JCA, vendor CRM AI, and global HQ playbooks land on the same patent clock. What is happening inside your envelope, your uptake forecast, your SG&A per rep, your controller bench, and your portfolio narrative. And the intersection most commercial CFOs have not named yet: you do not have three scorecard problems, you have one.
Four moves across envelope, uptake, SG&A, and narrative
Route the commercial-intelligence decision through the in-licensing hurdle, not the CRM-licence page. Rebuild the uptake forecast as a live driver graph, not a quarterly deliverable. Re-plan rep-force and medical-affairs capacity against AI-augmented coverage. Write the LoE-and-pipeline thesis once, refresh continuously.
Five questions for your next launch review
The commercial-intelligence-infrastructure question. The JCA-uptake-gap question. The vendor-AI-without-capacity-re-plan question. The three-audiences-one-thesis question. The 2031-succession-bench question. Where your commercial leadership cannot agree on the answer is the conversation worth an hour on the agenda.
Calibrated for each seat at the table.